Ventracor Limited Release: Approval to Start US BTT trial

April 9, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Ventracor (ASX:VCR) has received approval from the US Food & Drug Administration (FDA) to begin enrolment in the US Bridge To Transplant (BTT) Pivotal Trial of the VentrAssist™ Left Ventricular Assist Device (LVAD).

Twitter
LinkedIn
Facebook
Email
Print

Australia Career advice Job search strategy